Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cue Biopharma, Inc. (CUE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4500-0.0400 (-1.61%)
At close: 04:00PM EDT
2.5100 +0.06 (+2.45%)
After hours: 04:58PM EDT
Advertisement

Cue Biopharma, Inc.

21 Erie Street
Cambridge, MA 02139
United States
617 949 2680
https://www.cuebiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees57

Key Executives

NameTitlePayExercisedYear Born
Mr. Daniel R. Passeri J.D., M.Sc., MSc.CEO & Director774.7kN/A1961
Dr. Anish Suri Ph.D.Pres & Chief Scientific Officer598.24kN/A1974
Ms. Kerri-Ann MillarChief Financial Officer496.56kN/A1970
Dr. Ronald D. Seidel III, Ph.D.Co-FounderN/AN/A1976
Dr. Rodolfo J. ChaparroCo-Founder & Sr. AdvisorN/AN/A1973
Dr. Steven C. AlmoCo-Founder and Chairman of Scientific & Clinical Advisory BoardN/AN/A1961
George B. Zavoico Ph.D.VP of Investor Relations & Corp. Devel.N/AN/AN/A
Mr. Colin G. Sandercock J.D., MSESr. VP, Gen. Counsel & Sec.N/AN/A1957
Dr. Kenneth J. Pienta M.D.Acting Chief Medical OfficerN/AN/A1960
Dr. Matteo Levisetti M.D.Sr. VP of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Cue Biopharma, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 6. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement